Anavex Life Sciences Corp (AVXL)

[WilliamMunny]

Joseph, I think that despite the fact that it received relatively few recs - no doubt because it came in the evening hours - this has to be one of the better posts of the week. People on this board are always consumed by every nuance of FDA trial procedures, statistical variances, comparable approvals and new precedence, all of which can be critical, but it is rarely if ever mentioned that there is also a court of public opinion which can somewhat color the FDA approval process. You rightly point out that Sabbagh, while tied to Biogen/Eisai's effort with lecanemab, was very much intrigued with the Anavex presentation on blarcamesine at CTAD 2022. He now comes in as Chairman of the SAB at AVXL with, as you point out, broad experience and connections in the industry and as a recognizable and respected source for the media in their efforts to analyze and present information related to developments in Alzheimer's research. You note in jest that "he could qualify as Anavex's head of PR." Well, Anavex will be in a war to grab media attention if the Alzheimer's 2b/3 data is as good as Herr Doktor Missling suggests, and his input (to both the company and the media) could be even more important to the success of approval than the company's head of PR, whoever that is.